However, the clinical use of customized NKG2A+ or NKG2A− Vδ2 T cells should be matched with the histopathologic features of HLA-E expression to tailor those immunotherapeutic protocols to exert the most powerful immune responses against cancers. This evidence concerns the gene HLA-E and cancer.